Ischemia Reperfusion Injury Therapeutics Market, By Treatment, By Injury, By End User, and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)-Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

PUBLISHED: August 3, 2023

PAGES: 233 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The global ischemia reperfusion injury therapeutics market is estimated to be valued at US$ 2.06 Bn in 2023 and is expected to exhibit a CAGR of 6% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 2.06 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	6.00%	2030 Value Projection:	US$ 3.09 Bn

Ischemia Reperfusion Injury Therapeutics Market - IMG1

Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of an ischemia injury include bradycardia, headache, hypertension, and seizures. Ischemia-reperfusion injury is associated with serious clinical manifestations, including myocardial hibernation, acute heart failure, cerebral dysfunction, gastrointestinal dysfunction, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. Ischemia-reperfusion injury is a critical medical condition that poses an important therapeutic challenge for physicians.

Market Dynamics

Increasing number of research and development activities by the key market players for the treatment of patients suffering from reperfusion injury is expected to drive the growth of market over the forecast period. For instance, on May 31, 2022, GNT Pharma, a pharmaceutical company,reported that Nelonemdaz is under clinical for phase I clinical trial. Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, acute myocardial infarction (AMI) and burn injury, cerebral infarction.

Furthermore, in September 2021, GNT Pharma, a pharmaceutical company, reported that the Korea Ministry of Food and Drug Safety (MFDS) had approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma's earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.

Key features of the study:

This report provides an in-depth analysis of the global ischemia reperfusion injury therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Revive Therapeutics Ltd., Faraday Pharmaceuticals, Abiomed, Omeros Corporation, Pharming Group N.V., Nyken B.V., Orexo AB, Opsona Therapeutics Limited, PledPharma AB, Prothix BV, Proteo, Inc., Amyndas Pharmaceuticals LLC, Prolong Pharmaceuticals, Stealth BioTherapeutics Inc., Zealand Pharma A/S, Antipodean Pharmaceuticals, Inc., Bayer AG, Angion Biomedica Corp., Bolder Biotechnology, Inc., Curatis Pharma GmbH, Biomedica Management Corporation, Ensemble Therapeutics Corporation, Gilead Sciences, Inc., and Erimos Pharmaceuticals, LLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global medical imaging equipment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ischemia reperfusion injury therapeutics market

Detailed Segmentation:

Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment:
- Drug Therapy
- Medicated Gas
- Others (Vitamin Therapy and among Others)
Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type:
- Heart Injury
- Kidney Injury
- Intestine Injury
- Other Injury (Brain Injuries and Among Others)
Global Ischemia Reperfusion Injury Therapeutics Market, By End user:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others(Academic and Research Institutes and among Others)
Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
- Revive Therapeutics Ltd.
- Faraday Pharmaceuticals
- Abiomed
- Omeros Corporation
- Pharming Group N.V.
- Nyken B.V.
- Orexo AB
- Opsona Therapeutics Limited
- PledPharma AB
- Prothix BV
- Proteo, Inc.
- Amyndas Pharmaceuticals LLC
- Prolong Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Zealand Pharma A/S
- Antipodean Pharmaceuticals, Inc.
- Bayer AG
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Curatis Pharma GmbH
- Biomedica Management Corporation
- Ensemble Therapeutics Corporation
- Gilead Sciences, Inc.
- Erimos Pharmaceuticals, LLC.

Product Code: CMI4105

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Injury Type
- Market Snapshot, By End user
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Top Market Players by Revenue

4. Global Ischemia Reperfusion Injury Therapeutics Market- COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Ischemia Reperfusion Injury Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
Medicated Gas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
Others (Vitamin Therapy and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends

6. Global Ischemia Reperfusion Injury Therapeutics Market, By Injury Type, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Heart Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
Kidney Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
Intestine Injury
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
- Segment Trends

7. Global Ischemia Reperfusion Injury Therapeutics Market, By End user, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
Others (Academic and Research Institutes and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)

8. Global Ischemia Reperfusion Injury Therapeutics Market, By Region, 2018-2030, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2018-2030, (US$ Billion)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018- 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Injury Type, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2018-2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Revive Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Faraday Pharmaceuticals
Abiomed
Omeros Corporation
Pharming Group N.V.
Nyken B.V.
Orexo AB
Opsona Therapeutics Limited
PledPharma AB
Prothix BV
Proteo, Inc.
Amyndas Pharmaceuticals LLC
Prolong Pharmaceuticals
Stealth BioTherapeutics Inc.
Zealand Pharma A/S
Antipodean Pharmaceuticals, Inc.
Bayer AG
Angion Biomedica Corp.
Bolder Biotechnology, Inc.
Curatis Pharma GmbH
Biomedica Management Corporation
Ensemble Therapeutics Corporation
Gilead Sciences, Inc.
Erimos Pharmaceuticals, LLC.